Chronic lymphocytic leukemia and autoimmunity: a systematic review

Area of Science:

• Hematology
• Immunology
• Oncology

Background:

• Chronic lymphocytic leukemia (CLL) is frequently linked to immune system disturbances.
• The association between CLL and autoimmune cytopenias, specifically autoimmune hemolytic anemia and immune thrombocytopenia, is well-documented.
• Mechanisms involving leukemic cells in producing polyclonal autoantibodies are increasingly understood.

Purpose of the Study:

• To review the relationship between CLL and autoimmune cytopenias.
• To discuss the prognostic implications of autoimmune cytopenias in CLL.
• To examine the impact of chemo-immunotherapy on autoimmune hemolysis and the potential for autoimmune cytopenia preceding CLL diagnosis.

Main Methods:

• Literature review of recent studies on CLL and immune disturbances.
• Analysis of prognostic data comparing autoimmune cytopenias with bone marrow infiltration.
• Evaluation of treatment strategies for active hemolysis in CLL patients.

Main Results:

• Autoimmune cytopenia in CLL is not necessarily a poor prognostic indicator; immune-mediated cases may have better outcomes than those due to marrow infiltration.
• Concerns regarding fludarabine-induced hemolysis are less relevant with current chemo-immunotherapy.
• Autoimmune cytopenia can occur in monoclonal B-cell lymphocytosis, detectable by flow cytometry, suggesting it may precede CLL.
• No increased risk of non-hemiplegic autoimmune disorders in CLL, nor increased CLL risk in non-hemiplegic autoimmunity.

Conclusions:

• Immune disorders are integral to CLL, and understanding their mechanisms is crucial for comprehending the disease.
• Autoimmune cytopenias in CLL may be associated with a favorable prognosis.
• Further research into the interplay between neoplastic and immune components in CLL is warranted.